Veradermics, Incorporated
MANE
$103.90
-$4.23-3.91%
NYSE
| 12/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.82M | 1.02M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.01M | 5.97M | |||
| Operating Income | -23.01M | -5.97M | |||
| Income Before Tax | -21.85M | -5.66M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.85M | -5.66M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.85M | -5.66M | |||
| EBIT | -23.01M | -5.97M | |||
| EBITDA | -- | -- | |||
| EPS Basic | -37.62 | -8.79 | |||
| Normalized Basic EPS | -18.21 | -4.80 | |||
| EPS Diluted | -37.62 | -8.79 | |||
| Normalized Diluted EPS | -18.21 | -4.80 | |||
| Average Basic Shares Outstanding | 749.80K | 736.90K | |||
| Average Diluted Shares Outstanding | 749.80K | 736.90K | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||